Meta-analysis of 24-Hour Intraocular Pressure Studies Evaluating the Efficacy of Glaucoma Medicines

Ophthalmology

Volumn 115, Issue 7, 2008, Pages

  Stewart, William C ^a,b   Konstas, Anastasios G P ^c   Nelson, Lindsay A ^d   Kruft, Bonnie ^d  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Glaucoma Unit   (Greece)

^d Charleston Research Company LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

ABNORMAL SENSATION; ARTICLE; BURNING SENSATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRY EYE SENSATION; EVENING DOSAGE; EXFOLIATION SYNDROME; FOREIGN BODY SENSATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATOPATHY; META ANALYSIS; MONOTHERAPY; MORNING DOSAGE; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STINGING SENSATION; SUPINE POSITION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 45849120264     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.10.004     Document Type: Article

References (41)

1. Asrani S., Zeimer R., Wilensky J., et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 9 (2000) 134-142
2. Stewart W.C., Day D.G., Jenkins J.N., et al. Mean intraocular pressure and progression based on corneal thickness in primary open-angle glaucoma. J Ocul Pharmacol Ther 22 (2006) 26-33
3. Jonas J.B., Budde W., Stroux A., et al. Single intraocular pressure measurements and diurnal intraocular pressure profiles. Am J Ophthalmol 139 (2005) 1136-1137
4. Barkana Y., Anis S., Liebmann J., et al. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol 124 (2006) 793-797
5. Hughes E., Spry P., and Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma 12 (2003) 232-236
6. Wilensky J.T. The role of diurnal pressure measurements in the management of open angle glaucoma. Curr Opin Ophthalmol 15 (2004) 90-92
7. Stewart W.C., Chorak R.P., Hunt H.H., and Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 116 (1993) 176-181
8. Stewart W.C., Day D.G., Jenkins J.N., et al. Mean intraocular pressure and progression based on corneal thickness in primary open-angle glaucoma. J Ocul Pharmacol Ther 22 (2006) 26-33
9. Stewart W.C., Kolker A.E., Sharpe E.D., et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol 130 (2000) 274-279
10. Konstas A.G., Maltezos A.C., Gandi S., et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 128 (1999) 15-20
11. Konstas A.G., Mikropoulos D., Kaltsos K., et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 113 (2006) 446-450
12. Konstas A.G., Nakos E., Tersis I., et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 133 (2002) 753-757
13. Orzalesi N., Rossetti L., Bottoli A., and Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113 (2006) 239-246
14. Fogagnolo P., Rossetti L., Mazzolani F., and Orzalesi N. Circadian variations in central corneal thickness and intraocular pressure in patients with glaucoma. Br J Ophthalmol 90 (2006) 24-28
15. Verhagen A.P., de Vet H.C., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51 (1998) 1235-1241
16. Konstas A.G., Mantziris D.A., Cate E.A., and Stewart W.C. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 115 (1997) 975-979
17. Wolf F.M. Meta-analysis: Quantitative Methods for Research Synthesis (1986), Sage Publications, Newbury Park, CA 20-21
18. van der Valk R., Webers C.A., Schouten J.S., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112 (2005) 1177-1185
19. Konstas A.G., Kozobolis V.P., Katsimpris I.E., et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 114 (2007) 653-657
20. Netland P.A., Landry T., Sullivan K., et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132 (2001) 472-484
21. Parrish R.K., Palmberg P., Sheu W.P., and XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135 (2003) 688-703
22. Boyle J.E., Ghosh K., Gieser D.K., and Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 106 suppl (1999) 10-16
23. Sharpe E.D., Day D.G., Beischel C.J., et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce the intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 88 (2004) 953-956
24. Toris C.B., Zhan G.L., Yablonski M.E., and Camras C.B. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. J Glaucoma 13 (2004) 210-215
25. Topper J.E., and Brubaker R.F. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 26 (1985) 1315-1319
26. Liu J.H., Kripke D.F., and Weinreb R.N. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 138 (2004) 389-395
27. Quaranta L., Gandolfo F., Turano R., et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 47 (2006) 2917-2923
28. Orzalesi N., Rossetti L., Bottoli A., et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 121 (2003) 453-457
29. Orzalesi N., Rossetti L., Invernizzi T., et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41 (2000) 2566-2573
30. Stewart W.C., Stewart J.A., Day D.G., et al. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye 18 (2004) 990-995
31. Stewart W.C., Stewart J.A., Day D., and Sharpe E.D. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand 81 (2003) 242-246
32. Konstas A.G., Stewart W.C., Topouzis F., et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 131 (2001) 729-733
33. Konstas A.G., Lake S., Economou A.I., et al. 24-hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 124 (2006) 1553-1557
34. Konstas A.G., Kozobolis V.P., Tsironi S., et al. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology 115 (2008) 99-103
35. Konstas A.G., Boboridis K., Tzetzi D., et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 123 (2005) 898-902
36. Konstas A.G., Katsimbris J.M., Lallos N., et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 112 (2005) 262-266
37. Alm A., Stjernschantz J., and Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 102 (1995) 1743-1752
38. Camras C.B., and United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month masked, multicenter trial in the United States. Ophthalmology 103 (1996) 138-147
39. Watson P., Stjernschantz J., and Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103 (1996) 126-137
40. Sherwood M., Brandt J., and Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 45 suppl (2001) S361-S368
41. Clineschmidt C.M., Williams R.D., Snyder E., and Adamsons I.A. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 106 suppl (1999) 17-24